Trending Articles

article thumbnail

Healthy eating in midlife linked to overall healthy aging

Science Daily: Pharmacology News

Maintaining a healthy diet rich in plant-based foods, with low to moderate intake of healthy animal-based foods and lower intake of ultra-processed foods, was linked to a higher likelihood of healthy aging -- defined as reaching age 70 free of major chronic diseases and with cognitive, physical, and mental health maintained, according to a new study.

Disease 326
article thumbnail

State-of-the-art covalent virtual screening with AlphaFold3

Covalent Modifiers

Yoav Shamir, Nir London bioRxiv 2025.03.19.642201; doi: [link] Recent years have seen an explosion in the prominence of covalent inhibitors as research and therapeutic tools. However, a lag in application of computational methods for covalent docking slows progress in this field. AI models such as AlphaFold3 have shown accuracy in ligand pose prediction but were never assessed for virtual screening.

Research 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

HHS to cut 10,000 staff in major restructuring under RFK Jr.

BioPharma Drive: Drug Pricing

The FDA will lose about 3,500 employees under the plans, although HHS said drug, medical device and food reviewers will not be affected.

FDA 321
article thumbnail

FDA OKs Amvuttra To Treat Heart Conditions

Drugs.com

MONDAY, March 24, 2025 -- The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra (vutrisiran), is made by Alnylam Pharmaceuticals and is used to.

FDA 279
article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

1,2,3‐Triazole Tethered Spiro[Indoline‐Oxirane] Derivatives Induce Anticancer Effects in Human Hepatoma Cells

Chemical Biology and Drug Design

Synthesis and anticancer studies of spiro[indoline-oxirane] derivatives. ABSTRACT Epoxides are well-known compounds as anticancer agents. In this article, we present the synthesis of novel 3-phenyl-1-((1-aryl-1 H -1,2,3-triazol-5-yl)methyl)spiro[indoline-3,2-oxiran]-2-one derivatives by the regioselective reaction of sulfur ylides with 1,2,3-triazole-tethered isatins and their anticancer effects on hepatocellular carcinoma (HCC) cells HepG2 and HCCLM3.

Research 100

More Trending

article thumbnail

Methods for Kinetic Evaluation of Reversible Covalent Inhibitors from Time-Dependent IC50 Data

Covalent Modifiers

L. Mader and J. W. Keillor, RSC Med. Chem., 2025 DOI: 10.1039/D5MD00050E Potent reversible covalent inhibitors are often slow in establishing their covalent modification equilibrium, resulting in time-dependent inhibition. While these inhibitors are commonly assessed using IC50 values, there are no methods available to analyze their time-dependent IC50 data to provide their inhibition (Kiand Ki*) and covalent modification rate (k5and k6) constants, leading to difficulty in accurately ranking dru

Drugs 130
article thumbnail

First Prader-Willi drug to reduce hunger approved by FDA

BioPharma Drive: Drug Pricing

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

FDA 317
article thumbnail

Measles Outbreak Leads to Dangerous Vitamin A Toxicity

Drugs.com

FRIDAY, March 28, 2025 -- As a measles outbreak spreads across U.S., doctors are now seeing a new and unexpected danger: Children getting sick from taking too much vitamin A.At Covenant Childrens Hospital in Lubbock, Texas, several unvaccinated c.

Doctors 278
article thumbnail

An effort based at Broad is fostering dialogue between autism researchers, advocates, and families

Broad Institute

An effort based at Broad is fostering dialogue between autism researchers, advocates, and families By Leah Eisenstadt March 25, 2025 Breadcrumb Home An effort based at Broad is fostering dialogue between autism researchers, advocates, and families In a Q&A, autism researchers and advocates talk about a project theyve launched to encourage productive conversations on key issues in autism research.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

'Low-sugar' vaccine can provide broad immunity against coronavirus variants

Science Daily: Pharmacology News

Early animal studies show that a single vaccine could protect the recipient from different variants of the coronaviruses that cause COVID-19, the flu and the common cold. In addition to creating antibodies that target a specific region of the spike protein that doesn't mutate, the vaccine removes the sugar coat from the virus that allows it to hide in the body.

Vaccine 293
article thumbnail

The evolution of AI in drug discovery: learning from history’s mistakes (Part 2)

Drug Target Review

Sujeegar Jeevanandam, an expert with 13 years of experience in life sciences R&D, offers valuable insights into the current state and future trajectory of artificial intelligence in drug discovery. Having previously drawn parallels with industry adoption of electronic lab notebooks in part 1 , this article expands on his vision for the future of the industry, sharing his forward-thinking ideas and practical recommendations.

article thumbnail

Wave to seek approval of Duchenne drug after mid-stage study data

BioPharma Drive: Drug Pricing

The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

Treatment 258
article thumbnail

Gum May Be a Hidden Source of Microplastics

Drugs.com

WEDNESDAY, March 26, 2025 -- That stick of gum you’re chewing? It might be minty fresh, but it could also come with a little something extra: tiny bits of plastic. A new study finds that one piece of gum can release hundreds -- possibly.

263
263
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Collaborative Drug Discovery's Inaugural Canadian User Group Meeting

Collaborative Drug

Collaborative Drug Discovery's Inaugural Canadian User Group Meeting

Drugs 165
article thumbnail

Chimpanzees act as 'engineers', choosing materials to make tools based on structural and mechanical properties

Science Daily: Pharmacology News

Researchers have discovered that chimpanzees living in Gombe Stream National Park in Tanzania employ a degree of engineering when making their tools, deliberately choosing plants that provide materials that produce more flexible tools for termite fishing.

article thumbnail

Aleta’s Novel T Cell Engagers

SugarCone Biotech

Aleta Bio recently announced that their scientists have created, characterized and validated novel classes of Immune Cell Engager therapeutics including T Cell Engagers (TCE) and CAR T Cell Engagers (Ref. 1). In this post we describe the technology in more detail. Weve published extensively on the CAR-T Engager class, exemplified by our Phase 1/2 clinical program that is evaluating the safety and efficacy of ALETA-001, a therapeutic that binds CD19-directed CAR-T cells to a second antigen, CD20

article thumbnail

Makary confirmed by Senate as FDA commissioner

BioPharma Drive: Drug Pricing

The Johns Hopkins surgeon will helm the agency as layoffs loom and important decisions on treatments for rare and infectious diseases await.

FDA 249
article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Kennedy Orders Takedown of Fake CDC Vaccine Web Page

Drugs.com

MONDAY, March 24, 2025 -- A fake web page designed to look like the U.S. Centers for Disease Control and Prevention's (CDC) vaccine safety site has been taken down on orders from health secretary Robert F. Kennedy Jr.The site was linked to.

Vaccine 263
article thumbnail

7 Steps to Define a Data Governance Structure for a Mid-Sized Bank (Without Losing Your Mind)

Perficient: Drug Development

A mid-sized bank I was consulting with for their data warehouse modernization project finally realized that data isn’t just some necessary but boring stuff the IT department hoards in their digital cave. It’s the new gold, the ticking time bomb of risk, and the bane of every regulatory report that’s ever come back with more red flags than a beach during a shark sighting.

article thumbnail

A safe nuclear battery that could last a lifetime

Science Daily: Pharmacology News

Lithium-ion batteries, used in consumer devices and electric vehicles, typically last hours or days between charges. However, with repeated use, they degrade and need to be charged more frequently. Now, researchers are considering radiocarbon as a source for safe, small and affordable nuclear batteries that could last decades or longer without charging.

Research 283
article thumbnail

Therapeutic Oligos 2025 Keynote Speakers Announced

Elrig

Therapeutic Oligos 2025 Keynote Speakers Announced ELRIG Announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025 Cambridge, UK, 25 March 2025: ELRIG, a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D site in Gothenburg, Sweden from 1415 May.

RNA 59
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Accelerate oncology drug development: A data-driven approach to clinical decisions

BioPharma Drive: Drug Pricing

Speed vs. success in oncology trials: Discover data-driven strategies to accelerate drug development.

article thumbnail

Novo Nordisk To Pay $2 Billion for New Weight Loss Drug

Drugs.com

TUESDAY, March 25, 2025 -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity and diabetes drug, the company announced March 24. The drug, called UBT251, is being developed.

article thumbnail

Mastering AWS Infrastructure as Code with Pulumi and Python

Perficient: Drug Development

Pulumi is a modern Infrastructure as Code (IaC) tool that allows you to define, deploy, and manage cloud infrastructure using general-purpose programming languages. Unlike Terraform, which uses HCL, Pulumi enables you to define infrastructure using Python, making it easier for developers to integrate infrastructure with application code. What Youll Learn How Pulumi works with AWS Setting up Pulumi with Python Deploying various AWS services with real-world examples Best practices and advanced tip

article thumbnail

3D nanotech blankets offer new path to clean drinking water

Science Daily: Pharmacology News

Researchers have developed a new material that, by harnessing the power of sunlight, can clear water of dangerous pollutants.

Research 282
article thumbnail

The Benefits of Digital Transformation in Generic Drug Development

Drug Patent Watch

Revolutionizing Generic Drug Development: The Power of Digital Transformation As the pharmaceutical industry continues to evolve, one thing is clear: digital transformation is no longer a luxury, but a necessity. At the forefront of this revolution is the generic drug development sector, where innovative technologies are streamlining processes, reducing costs, and improving patient outcomes.